Foreign pharmaceutical companies providing digital services in Russia face a distinct VAT registration sequence. Understand the key steps. Make an enquiry.
Foreign pharmaceutical companies supplying digital services to customers in Russia are subject to a structured electronic services VAT procedure administered by the Federal Tax Service (FTS). The regime covers cloud-based platforms, SaaS clinical-trial management tools, online medical databases, and similar digital products – regardless of whether the Russian recipient is a business or an individual end-user.
The procedural sequence differs depending on the supply model. For business-to-consumer (B2C) supplies, the foreign company is directly liable: it must self-register with the FTS using the dedicated online portal, obtain a Russian taxpayer identification number (INN), file quarterly VAT returns in Russian roubles, and remit the tax to the federal budget. For business-to-business (B2B) supplies, the Russian corporate customer typically acts as tax agent, withholding and remitting VAT on behalf of the foreign supplier. In-house counsel should confirm which model applies to each product line – a SaaS platform sold directly to Russian pharmacies at retail level will follow the B2C route; a licence granted to a Russian distributor will generally follow the B2B route.
In the pharmaceuticals sector, a threshold question arises before registration: whether the specific digital product falls within the scope of taxable electronic services under Russian tax legislation, or whether it qualifies under a narrower exclusion for certain regulated healthcare information services. FTS guidance has generally construed the scope broadly, so reliance on any exclusion carries audit risk.
Once registered, the foreign company must file quarterly – typically by the 25th day of the month following each quarter – and maintain supporting documentation in a format acceptable to the FTS. Non-registration by a company that is, on an objective assessment, within scope can trigger a FTS desk audit, back-assessment of unpaid tax, and interest accruing from the date of first taxable supply.
For foreign pharmaceutical companies reviewing their Russian digital-services footprint, early-stage analysis of product classification and supply-chain structure is the practical priority.
To discuss how this regime applies to your company's specific product lines or distribution structure, make an enquiry: info@vetrovpartners.com |
– Kristina Kornouhova Senior Lawyer, Practice Lead – Tax & Antitrust, Vetrov & Partners vetrovpartners.com/kornouhova/
Kristina Kornouhova heads the firm's tax controversy and antitrust practices. She advises Russian and foreign companies facing Federal Tax Service audits, transfer-pricing disputes, and FAS Russia proceedings.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry